{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tansley SL"],"funding":["Versus Arthritis","Wellcome Trust"],"pagination":["2204-8"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC4241891"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["53(12)"],"pubmed_abstract":["<h4>Objective</h4>Calcinosis is a major cause of morbidity in JDM and has previously been linked to anti-NXP2 autoantibodies, younger age at disease onset and more persistent disease activity. This study aimed to investigate the clinical associations of anti-NXP2 autoantibodies in patients with JDM stratified by age at disease onset.<h4>Methods</h4>A total of 285 patients with samples and clinical data were recruited via the UK Juvenile Dermatomyositis Cohort and Biomarker Study. The presence of anti-NXP2 was determined by both immunoprecipitation and ELISA. Logistic regression analysis was performed to assess the age-dependent relationship between anti-NXP2 and the development of calcinosis and disease activity measures.<h4>Results</h4>We identified anti-NXP2 autoantibodies in 56 patients"],"journal":["Rheumatology (Oxford, England)"],"pubmed_title":["Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset."],"pmcid":["PMC4241891"],"funding_grant_id":["14518","085860","18474"],"pubmed_authors":["Juvenile Dermatomyositis Research Group","Arnold K","Shaddick G","McHugh NJ","Wedderburn LR","Betteridge ZE","Tansley SL","Gunawardena H"],"additional_accession":[]},"is_claimable":false,"name":"Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.","description":"<h4>Objective</h4>Calcinosis is a major cause of morbidity in JDM and has previously been linked to anti-NXP2 autoantibodies, younger age at disease onset and more persistent disease activity. This study aimed to investigate the clinical associations of anti-NXP2 autoantibodies in patients with JDM stratified by age at disease onset.<h4>Methods</h4>A total of 285 patients with samples and clinical data were recruited via the UK Juvenile Dermatomyositis Cohort and Biomarker Study. The presence of anti-NXP2 was determined by both immunoprecipitation and ELISA. Logistic regression analysis was performed to assess the age-dependent relationship between anti-NXP2 and the development of calcinosis and disease activity measures.<h4>Results</h4>We identified anti-NXP2 autoantibodies in 56 patients","dates":{"release":"2014-01-01T00:00:00Z","publication":"2014 Dec","modification":"2026-05-07T03:06:03.013Z","creation":"2026-04-07T22:33:42.704Z"},"accession":"S-EPMC4241891","cross_references":{"pubmed":["24987158"],"doi":["10.1093/rheumatology/keu259"]}}